STANDARD BIOTLS (LAB)
(Delayed Data from NSDQ)
$2.29 USD
+0.18 (8.53%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $2.28 -0.01 (-0.44%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Brokerage Reports
Standard BioTools Inc. [LAB]
Reports for Purchase
Showing records 1 - 11 ( 11 total )
Company: Standard BioTools Inc.
Industry: Medical - Instruments
Company: Standard BioTools Inc.
Industry: Medical - Instruments
3Q23 Exceeds Estimates, FY23 Guidance Reiterated
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Standard BioTools Inc.
Industry: Medical - Instruments
LAB and SLGC All-Stock Merger, Complementary Technologies Redefining Translational Research
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Standard BioTools Inc.
Industry: Medical - Instruments
Company: Standard BioTools Inc.
Industry: Medical - Instruments
Real-World Mass Cytometry and Spatial Biology Takeaways from Philadelphia CyTOF User Group Meeting
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Standard BioTools Inc.
Industry: Medical - Instruments
Company: Standard BioTools Inc.
Industry: Medical - Instruments
Company: Standard BioTools Inc.
Industry: Medical - Instruments
2Q23 - Exceeds Estimates, Strong Execution in Spatial Biology
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Standard BioTools Inc.
Industry: Medical - Instruments
Company: Standard BioTools Inc.
Industry: Medical - Instruments
Initiating Coverage; Unique Technology, Management and Board - Overweight with $4 PT
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Standard BioTools Inc.
Industry: Financial - Investment Bank
ValuEngine Detailed Valuation Report for LAB
Provider: VALUENGINE, INC
|